MRNA vs. WST: Moderna vs. West Pharmaceutical Services Stock Comparison

Company Profile

Moderna (MRNA) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MRNA is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas West Pharmaceutical Services (WST) sees a more moderate 603.86K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile West Pharmaceutical Services (WST) reports 21.23%, ranking against industry peers normally.

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile West Pharmaceutical Services (WST) reports 18.81%, ranking against industry peers normally.

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile West Pharmaceutical Services (WST) reports 25.37%, ranking against industry peers normally.

Profitability Metrics

Growth

West Pharmaceutical Services (WST) at 6.25% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: West Pharmaceutical Services (WST) reports EPS growth of 1.49%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.

Both Moderna (MRNA) at 0.19 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Moderna (MRNA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.

Moderna (MRNA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: West Pharmaceutical Services (WST) trades at 44.87 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

West Pharmaceutical Services (WST) at 8.20 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

Both Moderna (MRNA) at 11.58 and West Pharmaceutical Services (WST) at 9.40 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics